CN Patent

CN119119190A — 黑皮质素受体配体

Assigned to Ipsen Pharma SAS · Expires 2024-12-13 · 1y expired

What this patent protects

本发明涉及根据式(R 2 R 3 )‑A 1 ‑c(A 2 ‑A 3 ‑A 4 ‑A 5 ‑A 6 ‑A 7 ‑A 8 ‑A 9 )‑A 10 ‑R 1 的化合物，和其可药用盐，其作为一种或多种黑皮质素受体的配体，涉及使用此类化合物治疗哺乳动物的方法和包含所述化合物的药物组合物。

USPTO Abstract

本发明涉及根据式(R 2 R 3 )‑A 1 ‑c(A 2 ‑A 3 ‑A 4 ‑A 5 ‑A 6 ‑A 7 ‑A 8 ‑A 9 )‑A 10 ‑R 1 的化合物，和其可药用盐，其作为一种或多种黑皮质素受体的配体，涉及使用此类化合物治疗哺乳动物的方法和包含所述化合物的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN119119190A
Jurisdiction
CN
Classification
—
Expires
2024-12-13
Drug substance claim
No
Drug product claim
No
Assignee
Ipsen Pharma SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.